A look at Esperion Therapeutics Inc’s (ESPR) recent performance gives investors their first glimpse of hope.

On Monday, Esperion Therapeutics Inc (NASDAQ: ESPR) was -1.38% drop from the session before settling in for the closing price of $0.92. A 52-week range for ESPR has been $0.82 – $3.94.

Healthcare Sector giant saw their annual sales surged by 44.77% over the last five years. When this article was written, the company’s average yearly earnings per share was at 84.04%. With a float of $194.67 million, this company’s outstanding shares have now reached $195.85 million.

The firm has a total of 304 workers. Let’s measure their productivity. In terms of profitability, gross margin is 79.35%, operating margin of 16.37%, and the pretax margin is -15.57%.

Esperion Therapeutics Inc (ESPR) Insider Activity

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 1.76%, while institutional ownership is 58.73%. The most recent insider transaction that took place on Apr 17 ’25, was worth 106. In this transaction Chief Commercial Officer of this company sold 108 shares at a rate of $0.98, taking the stock ownership to the 370,218 shares. Before that another transaction happened on Apr 17 ’25, when Company’s Chief Financial Officer sold 8 for $0.96, making the entire transaction worth $8. This insider now owns 481,702 shares in total.

Esperion Therapeutics Inc (ESPR) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 84.04% per share during the next fiscal year.

Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators

You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.54.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.27, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.21 in one year’s time.

Technical Analysis of Esperion Therapeutics Inc (ESPR)

Analysing the last 5-days average volume posted by the [Esperion Therapeutics Inc, ESPR], we can find that recorded value of 4.7 million was better than the volume posted last year of 4.64 million. As of the previous 9 days, the stock’s Stochastic %D was 34.77%. Additionally, its Average True Range was 0.10.

During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 2.83%, which indicates a significant decrease from 20.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 94.74% in the past 14 days, which was higher than the 86.15% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.4290, while its 200-day Moving Average is $1.9617. Now, the first resistance to watch is $0.9503. This is followed by the second major resistance level at $0.9932. The third major resistance level sits at $1.0239. If the price goes on to break the first support level at $0.8767, it is likely to go to the next support level at $0.8460. Should the price break the second support level, the third support level stands at $0.8031.

Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats

There are 198,149K outstanding shares of the company, which has a market capitalization of 179.78 million. As of now, sales total 332,310 K while income totals -51,750 K. Its latest quarter income was 69,110 K while its last quarter net income were -21,320 K.